Biotech China 2014

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Age-related susceptibility of retinal function and blood flow to intraocular pressure challenge RANZCO 41st Annual Scientific Congress November, 2009
2. All the blood flows dark Normal pressure glaucoma symposia, RANZCO 41st Annual Scientific Congress November, 2009
3. Wound healing in the post-op period RANZCO 41st Annual Scientific Congress November, 2009
4. Challenges in glaucoma management RANZCO 41st Annual cientific Congress November, 2009
5. The effect of laser therapy on symptoms in primary angle-closure RANZCO 41st Annual Scientific Congress November, 2009
6. Cell polarity genes and corneal wound healing: In vivo role of scribble RANZCO 41st Annual Scientific Congress November, 2009
7. Rural emergency doctor's training from the ophthalmology perspective. RANZCO 41st Annual Scientific Congress November, 2009
8. Disc assessment for optic neuropathy: In the eye of the beholder? RANZCO 41st Annual Scientific Congress November, 2009
9. Bevacizumab use in trabeculectomy blebs RANZCO 41st Annual Scientific Congress November, 2009
10. Glaucoma and the aging optic nerve University of Melbourne, Faculty of Medicine, Dentistry & Health Services, Dean’s Lecture Series, Public Forum October, 2009
11. Melbourne Ophthalmic Alumni Meeting 2009 August, 2009
12. Glaucoma and the aging optic nerve Walter and Eliza Hall Institute Molecular Medicine Division Seminar August, 2009
13. Pursuing valid end-points for surgical research a new model of glaucoma surgery. Melbourne Ophthalmic Alumni Meeting 2009 August, 2009
14. Glaucomatous optic nerve assessment in international ophthalmology trainees: The GONE Project II. Melbourne Ophthalmic Alumni Meeting 2009 August, 2009
15. Dietary restriction reduces agerelated susceptibility of optic nerve to intraocular pressure injury. Melbourne Ophthalmic Alumni Meeting 2009 August, 2009
16. Role of Bevacizumab in trabeuculectomy Melbourne Ophthalmic Alumni Meeting 2009 August, 2009
17. Cell polarity genes and corneal wound healing: In vivo role of scribble Melbourne Ophthalmic Alumni Meeting 2009 August, 2009
18. Peripheral artery disease and glaucoma: The Singapore Malay eye study Melbourne Ophthalmic Alumni Meeting 2009 August, 2009
19. Disc assessment for optic Neuropathy: In the eye of the beholder? Melbourne Ophthalmic Alumni Meeting 2009 August, 2009
20. Auditory processing deficits in individuals with glaucoma Melbourne Ophthalmic Alumni Meeting 2009 August, 2009
21. laucoma management and progression, when monotherapy is not enough Dr Francesco Oddone Tour August, 2009
22. Glaucoma Australia, Twilight meeting, Melbourne August, 2009
23. 21st Birthday Glaucoma Meeting August, 2009
24. Avastin post-trabeculectomy National Glaucoma Week, Glaucoma Meeting August, 2009
25. Mouse: ageing and functional responses to IOP National Glaucoma Week, Glaucoma Meeting August, 2009
26. Results of the recent blood flow in glaucoma consensus report World Glaucoma Congress July, 2009
27. Clinician Scientist Symposium, Aging and mitochondrial dysfunction in glaucoma World Glaucoma Congress July, 2009
28. Keeping an eye on opportunities in neuroscience Neurosciences Victoria, Scientific Advisory Council meeting July, 2009
29. Focusing on Glaucoma-an information session CERA community briefing session July, 2009
30. IOP and Beyond, Natural history of glaucomatous disease World Glaucoma Congress July, 2009
31. World Glaucoma Congress July, 2009
32. Best of American Glaucoma Society, Micronutrients in glaucoma. World Glaucoma Congress July, 2009
33. Translational Science, Structural and functional testing World Glaucoma Congress July, 2009
34. Natural history of glaucomatous disease World Glaucoma Congress July, 2009
35. Glaucoma and the aging optic nerve Excitable Cells 2009, St Vincents Hospital June, 2009
36. ARVO Update Update on Recent Glaucoma Research to local Ophthalmic Community June, 2009
37. ARVO, May, 2009
38. New ideas in glaucoma ARVO 2009 May, 2009
39. What damages ganglion cells in glaucoma? ARVO 2009 May, 2009
40. Glaucoma Research Update CERA Science Seminars, update session for general Ophthalmologists April, 2009
41. Gerard Crock Inaugural Public Lecture March, 2009
42. New Science Update Symposium. American Glaucoma Society March, 2009
43. Diet modification and neuroprotection American Glaucoma Society March, 2009
44. Recharacterisation of the RGC-5 retinal ganglion cell line ARVO January, 2009
45. Factors associated with non-adherence to ocular hypotensive treatment in patients with glaucoma ARVO January, 2009
46. Intermittent fasting reverses age-related vulnerability of retinal ganglion cells to pressure induced oxidative stress ARVO January, 2009
47. Comparison of differentiation protocols for RGC-5 ARVO January, 2009
48. Decreased mitochondrial oxidative phosphorylation in autosomal dominant optic atrophy ARVO January, 2009
49. Age-related susceptibility of retina and optic nerve to intraocular pressure injury. ARVO January, 2009
50. Readability of prescription labels and medication recall in a population of tertiary referral glaucoma patients ARVO January, 2009
51. AAO November, 2008
52. Angle closure surrounds you! RANZCO 2008 November, 2008
53. Translating Glaucoma Research Glaucoma Australia Public Lecture October, 2008
54. Glaucoma Research Update CERA Update Meeting for General Ophthalmologists September, 2008
55. Glaucoma Research from populations to mitochondria Glaucoma Australia 20th Anniversary Celebrations July, 2008
56. Progression in Glaucoma World 2008 Ophthalmology Congress July, 2008
57. ARVO Update Update on Recent Glaucoma Research to local Ophthalmic Community June, 2008
58. Neuroprotection ARVO 2008 May, 2008
59. Combined cyclodiode and Intravitreal bevacizumab in neovascular glaucoma ANZGIG March, 2008
60. Effect of anti-VEGF antibodies Tenon's fibroblast scarring activity ANZGIG Annual Congress March, 2008
61. Medical therapy with topical prostaglandin does not affect outcomes with selective laser trabeculoplasty ANZGIG March, 2008
62. Age-related mitochondrial dysfunction and the vulnerability of retinal ganglion cells to oxidative stress in glaucoma ORIA Symposium, RANZCO January, 2008
63. Focusing on the optic nerve Australian Orthoptics Association Annual Meeting January, 2008
64. Fourth ARVO/Pfizer Ophthalmics Research Institute Conference Working Group January, 2008
65. Anti-VEGF treatment on Human Tenon's fibroblast scarring activity ARVO January, 2008
66. An aging study of oxidative stress-related markers in the mouse retina ARVO January, 2008
67. Pharmacological approaches to neuroprotection SEAGIG Neuroprotection Symposium January, 2008
68. Secondary Glaucoma Following Paediatric Cataract Surgery European Glaucoma Society January, 2008
69. World Glaucoma Congress July, 2007
70. Watching ganglion cells die World Glaucoma Congress July, 2007
71. Implications of the modulation of wound healing to clinical practice World Glaucoma Congress July, 2007
72. Imaging sick and dying retinal ganglion cells World Glaucoma Congress July, 2007
73. Symposium Lecture Neuroprotection Symposium Recent Advances in Glaucoma Neuroprotection July, 2007
74. Watching ganglion cells die World Glaucoma Congress Closing Symposium July, 2007
75. Manipulating surgical pathways World Glaucoma Congress 2007 July, 2007
76. Basic science of intraocular pressure World Glaucoma Congress 2007 July, 2007
77. Glaucoma Surgery World Glaucoma Congress 2007 July, 2007
78. Intraocular Pressure Beyond the Optic Nerve Series Allergan Presentations: Geelong June, 2007
79. The Optic Nerve in Glaucoma Victorian College Optometry, Technical Meeting June, 2007
80. Putting Glaucoma under the Microscope Glaucoma Australia Public Lecture June, 2007
81. New Research Findings from ARVO 2007 Lecture to Regional Ophthalmogists May, 2007
82. Glaucoma Detection Orthoptic Continuing Education Series May, 2007
83. Focusing on Glaucoma CERA Public Lecture April, 2007
84. ANZGIG 2007 Scientific Meeting March, 2007
85. Prostaglandin pharmacology lessons from the mouse Asia ARVO February, 2007
86. Chair- Neuroprotection Session Association of Pharmacology and Therapeutics Meeting 2007 February, 2007
87. Plenary Lecture Chair- Asia ARVO February, 2007
88. Glaucoma Research Dept of Optometry & Vision Sciences, University of Melbourne January, 2007
89. Mouse models in Glaucoma Research Asia-ARVO January, 2007
90. The role of the FP receptor in prostaglandin-mediated MMP up-regulation in the mouse eye. ARVO January, 2007
91. Elevated hydrostatic pressure triggers release of OPA1 and cytochrome C and induced apoptotic cell death in differentiated RGC-5 cells ARVO January, 2007
92. Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage in glaucoma models ARVO January, 2007
93. Moderator- Lens Biochemistry Session European Vision and Eye Research Spain October, 2006
94. Chair- Workshop Glaucoma Surgery 9th Annual Ocular Surgery and therapeutic Update February, 2006
95. Aqueous Humor Outflow Second Annual ARVO/Pfizer Ophthalmic Research Institute Conference Working Group January, 2006
96. Recent advances in perimetry selective visual field testing American Academy of ophthalmology Glaucoma Subspecialty Day January, 2006
97. MMP2 and MMP9 expression in the mouse eye and the effect of topical prostaglandin on MMP expression ARVO January, 2006
98. Hydrostatic pressure induces mitochondrial fission in differentiated RGC-5 cells. ARVO January, 2006
99. Optic disc examination and stereophotography Allergan SEAGIG Symposium January, 2006
100. Interferon-alpha and gamma sensitize human Tenon’s fibroblasts to mitomycin-C induced apoptosis through a caspase-3 dependent pathway ARVO January, 2006
101. Optic Disc Morphology in 6-yr old Australian Children RANZCO January, 2006
102. Trasscleral delivery of macromolecules to the retina enhanced by MMPs. ARVO January, 2006
103. The keys to successful trabeculectomy Alcon Pharmaceutical Advisory Summit San Francisco January, 2005
104. The uniocular therapeutic Trial Alcon Pharmaceutical Advisory Summit Miami January, 2005
105. Global risk assessment in glaucoma Moorfield’s Bicentennial Meeting January, 2005
106. Every millimetre counts - glaucoma is a surgical disease Ocular Drug and Surgical Update January, 2005
107. What is the value of the one-eyed therapeutic trial? Glaucoma Specialists Forum January, 2005
108. Mouse models in glaucoma World Glaucoma Conference January, 2005
109. MMP enhancement of macromolecular delivery to the posterior segment ARVO January, 2004
110. Advances in open Angle Glaucoma Department of Ophthalmology Southampton University January, 2004
111. Mouse models in glaucoma Moorfields Eye Hospital, University College London January, 2004
112. Effect of a single dose of latanoprost on intraocular pressure in FP receptor-knockout mice Association of Research in Vision and Ophthalmology January, 2004
113. Human serum reduces mitomycin-C cytotoxicity in Tenon’s fibroblasts ARVO January, 2004
114. Every millimeter does count: Glaucoma is a Surgical Disease 8th Annual Ocular Drug & Surgical Therapy Meeting January, 2004
115. Vertical cup: disc ratios in a nonglaucomatous population-based sample. The Blue Mountains Eye Study Association of Research in Vision and Ophthalmology January, 2003
116. Water-mediated lysis of lens epithelial cells- A candidate agent for preventing posterior capsule opacification Association of Research in Vision and Ophthalmology January, 2003
117. Safety study to examine the use of mitomycin-C, distilled water and triton-X for sealed irrigation of the capsular bag to prevent posterior capsule opacification in rabbits Association of Research in Vision and Ophthalmology January, 2003
118. Fibroblast apoptosis - resolution of ocular wound healing Eastern Shores Immunology Conference January, 2003
119. The use of trypan blue to identify the area of treatment during trabeculectomy with mitomycin-C or 5-fluorouracil Association of Research in Vision and Ophthalmology January, 2003
120. ARVO January, 2003
121. Is the 95th percentile of normal cup-disc ratio adjusted for disc size of use in determining the likelihood of glaucoma. Australian Ophthalmology and Visual Science Meeting, January, 2003
122. The variability of subTenon’s drug delivery for trabeculectomy. Royal Australian New Zealand College of Ophthalmologists, Annual Meeting, November, 2002
123. Distant evaluation of postoperative trabeculectomy cases International Congress of Ophthalmology April, 2002
124. Death receptors and LEC apoptosis European Association for Vision and Eye Research (EVER) October, 2001
125. The role of matrix metalloproteinases in lens epithelial cell migration, capsule contraction and posterior capsule opacification Oxford Ophthalmological Congress July, 2001
126. Death receptor-mediated apoptosis in a human lens epithelial cell line Association of Research in Vision and Ophthalmology January, 2001
127. Human Tenon's fibroblast/T lymphocyte interactions in the pathogenesis of chronic inflammation, aggressive scarring and the failure of high-risk glaucoma filtration surgery. Association of Research in Vision and Ophthalmology January, 2000
128. Mitomycin-C renders Tenon's fibroblasts susceptible to cytotoxic T-cell mediated cell death Association of Research in Vision and Ophthalmology January, 2000
129. The assessment of the foveal avascular zone in fluorescein angiography. A computer-based model Association of Research in Vision and Ophthalmology January, 2000
130. Pigment epithelial changes in persistent diabetic macular oedema. Association of Research in Vision and Ophthalmology January, 2000
131. Diurnal intraocular pressure monitoring in the management of glaucoma suspects. Royal College of Ophthalmologists Annual Congress January, 2000
132. Fas (CD95) and mitomycin-C-induced fibroblast apoptosis. Association of Research in Vision and Ophthalmology January, 1999
133. A new potential mechanism for inhibiting scarring. Foulds trophy Prize presentation Annual Congress of the Royal College of Ophthalmologists January, 1998
134. Fibroblast apoptosis as a potential mechanism for inhibiting scar formation. Keystone Symposium in Wound Healing January, 1998
135. Terminating scarring with mitomycin-C and Fas Oxford Ophthalmological Congress January, 1998
136. Fibroblast apoptosis and the regulation of conjunctival wound healing Ophthalmology and Vision Sciences. The Wellcome Trust June, 1997
137. Mitomycin C induced fibroblast apoptosis and thin drainage blebs Royal College of Ophthalmology Annual Congress May, 1997
138. Lymphocyte coculture augments Mitomycin-C induced fibroblast apoptosis British Society of Immunologists Annual Congress January, 1997
139. Lymphocyte coculture augments Mitomycin-C induced fibroblast apoptosis. British Society of Immunologists, Annual Congress January, 1997
140. The regulation of Mitomycin C induced apoptosis in human Tenon's capsule fibroblasts. Association of Research in Vision and Ophthalmology January, 1997
141. Mitomycin-C and 5-fluorouracil-induced apoptosis in Tenon's fibroblasts. Oxford Ophthalmology Congress July, 1996
142. Anti-metabolite induced apoptosis in Tenon's fibroblasts Association of Research in Vision and Ophthalmology January, 1996



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Monitoring RGCs in the real world Retinal Ganglion Cells April, 2010

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.